Imdelltra (Tarlatamab-Dlle) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
Resources
About MyLungCancerTeam
Powered By

Overview
Imdelltra is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive stage small cell lung cancer (SCLC) — cancer that has spread — whose disease has progressed after undergoing platinum-based chemotherapy. This indication received accelerated approval based on the overall response rate and duration of response. Continued approval may depend on verification and description of clinical benefit in a confirmatory trial. Imdelltra is also known by its drug name, tarlatamab-dlle.

Imdelltra belongs to the biologic drug category. It is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager, which means it helps the immune system target and destroy cancer cells. Scientists believe it works by binding to the DLL3 protein on cancer cells and activating T-cells to attack these cells.

How do I take it?
Prescribing information states that Imdelltra should be administered as an intravenous (IV) infusion over one hour. The treatment begins with a step-up dosing schedule to reduce the risk of cytokine release syndrome (CRS), a potential side effect. People receiving this medication are typically monitored closely for 22 to 24 hours following the start of the infusion on Cycle 1 Day 1 and Cycle 1 Day 8. They are advised to stay within one hour of an appropriate health care setting for 48 hours after these doses, accompanied by a caregiver.

Side effects
Common side effects of Imdelltra include fatigue, pyrexia (fever), dysgeusia (altered taste), decreased appetite, musculoskeletal pain, constipation, anemia, and nausea.

Rare but serious side effects may include CRS, which can be serious or life-threatening, and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS). Other serious side effects can include cytopenias (reduced blood cell counts), infections, hepatotoxicity (liver damage), hypersensitivity reactions, and harm to an unborn fetus when taken by a pregnant individual. 

People taking this drug may experience decreases in certain blood cells (lymphocytes, neutrophils, white blood cells, platelets, hemoglobin), potassium, and sodium, as well as increases in uric acid, activated partial thromboplastin time (a blood clotting test), and liver enzymes (aspartate aminotransferase and alanine aminotransferase).

For more information about this treatment, visit:

Label: Imdelltra (AMG757) — Tarlatamab-Dlle Kit — DailyMed

Imdelltra — Drugs.com
 

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in